In order to obtain possible veinotonic drugs acting through a a 2 receptor activation, we prepared clonidine analogues in which the 2-imino-imidazolidine was attached to various aliphatic or aromatic heterocycles. Among them, the two benzopyranic derivatives 16 and 22 exhibited interesting affinities (19 and 95 nM respectively on [ 3 H]rauwolscine binding, compared to 35 nM for clonidine). Their affinity for a a 1 receptors was found to be much lower: 7570 and 5030 nM for 16 and 22 respectively, suggesting 16 to be 400 times more selective for a a 2 than for a a 1 -adrenoceptors.
Venous pathology may result from deficiency of the venous wall contractility. The increase in venous system pressure is due to three main factors: increase of Ca 2ϩ concentration in the smooth muscle cells, decrease of endothelial nitric oxide production and decrease of a-adrenergic receptors (a-AR) of the venous system. 1) Our research efforts to find potentially veinotonic molecules were oriented towards aadrenergic compounds, namely a 2 -selective agonists, devoid of any vasoconstrictor side-effect due to a 1 -AR activation, a 2 -AR being relatively more abundant in veins than in arteries. [1] [2] [3] Furthermore, low lipophilicity was needed to avoid hematoencephalic resorption and thus to limit the molecules' central effects. It is also well known that imidazoline compounds enhance spontaneous mechanical activity in rat portal vein 4, 5) and antagonize the relaxant effects of the K-channel openers.
4-7)
Most a 2 -adrenergic agonists belong to the classes of aralkylimidazoline and aryliminoimidazolidine derivatives, best represented by clonidine and moxonidine. With the structure-activity relationships of these aryliminoimidazolidine derivatives in mind, [8] [9] [10] [11] we kept intact the 2-iminoimidazolidine fragment of the pharmacophore to preserve a good a 2 -AR binding and we only modified the aromatic moiety. Among the various structures of the R moiety linked to the imino group (Chart 1) the choice was made between aliphatic moiety and aromatic moiety which could be ortho substituted. We had a special interest in benzopyranic structures because coumarin and flavonoids are usually used as phlebotomic as well as vascular protecting agents. [12] [13] [14] Chemistry The final compounds were obtained by condensation of various amines with imidazoline or imidazolidine (Chart 2) bearing adequate leaving groups in position 2 either pre-existent, as methylthio, or formed in situ as chloro. Starting from 2-imidazolidinethione, the hydriodide salt of 2-methylmercaptoimidazoline was prepared by the action of iodomethane 15) and was heated with a moderate excess of a primary amine with or without solvent until the evolution of mercaptan was complete 16, 17) (method 1). Starting from Nacetylimidazolidin-2-one, 18 ) the 2-chloro derivative formed in situ with POCl 3 17,19) was condensed with the primary amine and the acetyl protecting group was finally hydrolyzed (method 2). The initial primary amines were commercially available (series A, B) or prepared according to published procedures (series C). [20] [21] [22] [23] [24] [25] [26] [27] The structures of all compounds were confirmed by IR, 1 H-NMR, 13 C-NMR and all final imidazolidine compounds were also confirmed by elemental analyses. 
Results and Discussion
Pharmacological tests were performed with a limited number of compounds to lead our syntheses rapidly towards products bearing the required activity.
The N-acetylated intermediates have not been tested because this substitution of the imidazolidine moiety reduces the positive charge on the heterocycle and strongly decreases the affinity for the a-AR that is tightly related to the formation of an ionic interaction between the N-cationic atom of the ligand and the highly conserved aspartate residue found in the helix 3 of the adrenoceptors and other G-protein coupled receptors that bind biogenic amines. 28 ) a 2 -AR affinities of the first few synthesized compounds (series A, B) were estimated. The poor results of their binding abilities in comparison with clonidine and yohimbine (Table 1) , a reminder that only very few products devoid of aromatic character, such as rilmenidine, have a 2 -adrenergic activity, 29) prompted us to prepare 2-(benzopyranylimino)imidazolines. To evaluate the a 2 -AR affinities of these compounds (series C) we used These two compounds showed good a 2 -AR specificity: their a 1 -AR affinities (IC 50 ϭ7570 and 5030 nM for 16 and 22 respectively) were low which suggests compounds 16 and 22 are respectively 50-400 times and 5-50 times more selective for a 2 -AR than for a 1 -AR. Similarly clonidine was approximately 15 times more selective for a 2 -AR than for a 1 -AR. Compound 16 is roughly as selective for a 2 -AR as idazoxan which showed an a 2 selectivity of 333.
Calculated log P (CLOGP) values of the titled compounds and analogs (Table 3) showed some differences for moxonidine, rilmenidine and compounds 1-5 and 10 (probably accounted for by errors in the CLOGP method in relation with the absence of fragments in the method). Other dissimilar values might be related to the differences in the underlying principles of the two methods used for calculations. Titled compounds showed a slightly lower lipophilicity than clonidine and rilmenidine; their weakly lipophilic features can help to limit the molecules' central effects. However their possible peripheral effects should be estimated after in vivo experiments because some closely related compounds as moxonidine and idazoxan which have low log P values still affect central nerve system. These preliminary results show that compound 16 exhibits good affinity for a 2 -AR, comparable to that of clonidine. Moreover its a 2 -AR selectivity is improved compared with that of clonidine and similar to that of idazoxan, which suggests that compound 16 is a potential veinotonic agent.
Experimental
Chemistry. General Procedures Melting points were determined with a Büchi 510 capillary apparatus and are uncorrected. The IR spectra were recorded on a Unicam SP1100 IR spectrophotometer using potassium bromide plates for liquid products and potassium bromide tablets for solid products; the frequencies are expressed in cm
Ϫ1
.
1 H-and 13 C-NMR spectra were recorded on a Brucker AC 200 spectrometer in CDCl 3 or dimethyl sulfoxide (DMSO)-d 6 solution. Chemical shifts are given in d (ppm) unit relative to internal reference Me 4 Si (s: singlet, d: doublet, t: triplet, q: quintet, m: multiplet, br: broad). Elemental analyses (C, H, N, Cl, I, O) were carried out in the Service Central d'Analyses, Centre National de la Recherche Scientifique, 69390 Vernaison, France, and were within Ϯ0.4% of theoretical values unless otherwise noted. Reaction progress and purity of products were checked by carrying out TLC using Silica Gel Merck 60F 254 ; the spots were visualised by UV and iodine vapour. The log P values were calculated by two methods: CLOGP method of Leo which is basically a fragment method that accounts for steric, electronic and hydrogen bonding interactions 30) and Ghose and Crippen's method which uses atom-type descriptors selected by regression procedure. 31) Synthesis of Benzopyranyl Amines 3-Aminocoumarin was prepared from salicylaldehyde and acetylglycine according to Chakravarty et al. 20, 21) 3-Amino-4-methylcoumarin was prepared from hippuric acid via the 2-phenyloxazoline-5-one according to Tripathy and Mukerjee. 22) 3-Aminochromone and 2-methyl-3-aminochromone were prepared by cyclization of 2Ј-hydroxy-2-nitroacetophenone by AcOCHO and Ac 2 O respectively followed by reduction of the 3-nitro moiety according to Becket and Ellis 23) and Tanaka et al. 24) The 2Ј-hydroxy-2-nitroacetophenone was obtained by nitration of 4-hydroxycoumarin followed by saponification according to Huebner and Link. 25) 3-Aminoflavone was obtained by nitrosation followed by reduction of the flavanone according to Oyamada and Fukawa 26) and to Shimizu and Nakazawa. 27) Synthesis of 2-Iminoimidazolidine Compounds (Method 1) 2-(4-Morpholinyl)iminoimidazolidine (1): A solution of 2-methylmercapto-4,5-dihydroimidazole hydriodide (6.1 g, 25 mmol) and N-aminomorpholine (5.1 g, 50 mmol) in ethanol (30 ml) was refluxed for 8 h. After cooling, the solution was evaporated to give a residue which was dissolved in water (10 ml). A precipitate was obtained by alkalization with 30% aqueous NaOH (30 ml). The precipitate was filtered and purified by crystallization from CHCl 3 . Yield 3.0 g (71%): mp 214°C (Lit. 216°C). 3 1-Acetyl-2-[2-(3,5-dichloropyridinyl)]iminoimidazolidine (7): A solution of 1-acetylimidazolidin-2-one (3.8 g, 30 mmol) and 2-amino-3,5-dichloropyridine (3.9 g, 30 mmol) in POCl 3 (30 ml) was refluxed for 3 h. POCl 3 was evaporated, and the residue was dissolved in ice-cooled water, and the aqueous solution was alkalinized by 30% aqueous NaOH until pH 8. The crude product was extracted by CHCl 3 (3ϫ20 ml), the collected extracts were dried over Na 2 SO 4 and concentrated under reduced pressure. Recrystallization from cyclohexane gave product 7. 1-Acetyl-2-(2-oxo-2H-benzopyran-3-yl)iminoimidazolidine (13): This compound was prepared from 1-acetylimidazolidin-2-one (1.3 g, 10 mmol), 3-aminocoumarin (1.6 g, 10 mmol) and POCl 3 (10 ml) and was recrystallized from ethanol. Yield 0.8 g (30%): mp 250°C (dec.), 2-(2-Oxo-2H-benzopyran-3-yl)iminoimidazolidine Hydrochloride (14): 13 (1.8 g, 7 mmol) was dissolved in 1 N HCl (10 ml) and water (20 ml) at 50°C. The cooled solution was alkalinized by dilute aqueous NaOH. The crude product was filtered, dried, and converted into its hydrochloride salt with gaseous HCl in ethanol. Yield 0.7 g (46%): mp 246°C (dec. 33) Rat forebrain membranes were incubated in triplicate at 25°C for 30 min, at the final concentration of 5.6 mg/ml of tissue, with [ 3 H]clonidine (5 nM) (Amersham), with tested compounds at various concentrations with buffer (50 mM Tris-HCl) alone at pH 7.5 (total binding), or with buffer containing clonidine (1 mM) (nonspecific binding) in a total volume of 2 ml. Membranes were filtered on Whatman GF/C fiberglass filter paper and washed with ice-cold buffer. Bound activity was then determined by liquid scintillation spectrometry. Specific binding was defined as the difference between total binding and nonspecific binding. The IC 50 values were determined after appropriate displacement results by the log-probit linear regression analysis. Clonidine and yohimbine were used as reference molecules.
Synthesis of 2-Iminoimidazolidine Compounds (Method 2). a) Condensations of the Amines with POCl
Competition with [ 3 H]Rauwolscine According to Diop et al. 34) Binding studies were performed in triplicate with rat crude cerebrocortical membranes incubated at 25°C for 30 min with [ 3 H]rauwolscine (1 nM) (Dupont NEN) with 10
Ϫ7
, 10 Ϫ6 and 10 Ϫ5 M concentrations of tested compounds, either with buffer (Tris-HCl, pHϭ7.5) alone (total binding), or with buffer containing 100 mM (Ϫ) noradrenaline (Sigma)(nonspecific binding) in a total volume of 300 ml. Membranes were filtered and washed with ice-cold incubation buffer using a cell harvester (Brandel). Bound radioactivity was determined by counting with a Beckman LS 6000 liquid scintillation counter. IC 50 values of tested compounds with corresponding ligand-receptors were calculated through linear regression analysis. These were mean values from 3 independent determinations.
Competition with [ 3 H]RX821002 According to Uhlen and Wikberg

35)
These assays were performed as previously reported, using [ 3 H]RX821002 (2 nM) (Dupont NEN), (Ϫ) adrenaline (10 mM) (Sigma) as nonspecific ligand, and yohimbine as the reference molecule. Results are given as IC 50 values as before. 36) These assays were performed as previously reported, using [ 3 H]prazosine (0.25 nM) (Dupont NEN) and prazosine (0.5 M) (Sigma) as nonspecific ligand, and a 60 min/25°C incubation. Results are given as IC 50 values as before.
Competition with [ 3 H]Prazosine According to Greengrass and Bremner
